Neuphoria Therapeutics Inc. SEC filings NEUP

Neuphoria Therapeutics Inc. has 420 filings in SEC EDGAR's recent list, going back to Sep 11, 2002. Its latest annual report, Form 10-K, was filed on Sep 18, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 15, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (material agreement, change to shareholder rights). The company's fiscal year ends on June 30.

Neuphoria Therapeutics Inc. SEC filings
Form Description Filed Period
SCHEDULE 13G Ownership over 5% (passive) Oct 5, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jul 28, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 6, 2026 —
4 Insider transaction Jan 21, 2026 Jan 20, 2026
4 Insider transaction Jan 21, 2026 Jan 20, 2026
4 Insider transaction Jan 21, 2026 Jan 20, 2026
4 Insider transaction Jan 21, 2026 Jan 20, 2026
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 29, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Dec 2, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 28, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 18, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Nov 10, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Nov 5, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Oct 31, 2025 —
SCHEDULE 13G Ownership over 5% (passive) Oct 31, 2025 —
SCHEDULE 13D Ownership over 5% (active) Oct 23, 2025 —
4 Insider transaction Oct 23, 2025 Oct 21, 2025
3 Initial insider ownership Oct 23, 2025 Oct 21, 2025
4 Insider transaction Sep 2, 2025 Aug 27, 2025
4/A Filing May 19, 2025 Apr 16, 2025
4 Insider transaction Apr 18, 2025 Apr 16, 2025
4 Insider transaction Apr 18, 2025 Apr 16, 2025
4 Insider transaction Apr 18, 2025 Apr 16, 2025
4 Insider transaction Apr 18, 2025 Apr 16, 2025
4 Insider transaction Apr 18, 2025 Apr 16, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13D/A Amended ownership over 5% (active) Jan 28, 2025 —
SC 13G Ownership over 5% (passive) Nov 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Nov 14, 2024 —
SC 13D/A Amended ownership over 5% (active) Oct 7, 2024 —
3 Initial insider ownership Jul 12, 2024 Jul 1, 2024
3 Initial insider ownership Jul 8, 2024 Jul 1, 2024
3 Initial insider ownership Jul 8, 2024 Jul 1, 2024
3 Initial insider ownership Jul 8, 2024 Jul 1, 2024
3 Initial insider ownership Jul 8, 2024 Jul 1, 2024
3 Initial insider ownership Jul 8, 2024 Jul 1, 2024
3 Initial insider ownership Jul 8, 2024 Jul 1, 2024
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
SC 13G Ownership over 5% (passive) Oct 30, 2023 —
SC 13G Ownership over 5% (passive) Oct 10, 2023 —
SC 13G Ownership over 5% (passive) Sep 29, 2023 —
SC 13G Ownership over 5% (passive) Feb 14, 2022 —
SC 13D Ownership over 5% (active) Dec 30, 2021 —

Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NEUP (Nasdaq)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Burlington, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1191070
Former names
BIONOMICS LIMITED/FI (until Dec 23, 2024)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.